{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:26:44Z","timestamp":1781677604860,"version":"3.54.5"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.juro.2015.11.073","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T01:22:30Z","timestamp":1450228950000},"page":"1903-1910","source":"Crossref","is-referenced-by-count":11,"title":["The Dose-Response Relationship of bacillus Calmette-Gu\u00e9rin and Urothelial Carcinoma Cell Biology"],"prefix":"10.1097","volume":"195","author":[{"given":"Gopitkumar","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Urology, Medical College of Wisconsin, Milwaukee, Wisconsin"},{"name":"Department of Biophysics (BK), Medical College of Wisconsin, Milwaukee, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical College of Wisconsin, Milwaukee, Wisconsin"},{"name":"Department of Biophysics (BK), Medical College of Wisconsin, Milwaukee, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanghong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical College of Wisconsin, Milwaukee, Wisconsin"},{"name":"Department of Biophysics (BK), Medical College of Wisconsin, Milwaukee, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YanLi","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical College of Wisconsin, Milwaukee, Wisconsin"},{"name":"Department of Biophysics (BK), Medical College of Wisconsin, Milwaukee, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaraman","family":"Kalyanaraman","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical College of Wisconsin, Milwaukee, Wisconsin"},{"name":"Department of Biophysics (BK), Medical College of Wisconsin, Milwaukee, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"See","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical College of Wisconsin, Milwaukee, Wisconsin"},{"name":"Department of Biophysics (BK), Medical College of Wisconsin, Milwaukee, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2015.11.073_bib1","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update","volume":"59","author":"Babjuk","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2015.11.073_bib2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5489\/cuaj.10051","article-title":"Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy","volume":"4","author":"Kassouf","year":"2010","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.juro.2015.11.073_bib3","series-title":"Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): Update","author":"Hall","year":"2007"},{"key":"10.1016\/j.juro.2015.11.073_bib4","article-title":"Immunotherapy of urinary bladder carcinoma: BCG and beyond","volume":"2012","author":"Luo","year":"2012","journal-title":"Adv Urol"},{"key":"10.1016\/j.juro.2015.11.073_bib5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.urolonc.2008.10.024","article-title":"Optimizing BCG therapy","volume":"27","author":"O'Donnell","year":"2009","journal-title":"Uro Oncol"},{"key":"10.1016\/j.juro.2015.11.073_bib6","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.eururo.2007.05.010","article-title":"What is the optimal BCG dose in non-muscle-invasive bladder cancer?","volume":"52","author":"Witjes","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2015.11.073_bib7","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.juro.2013.03.123","article-title":"Contributors to HMGB1 release by urothelial carcinoma cells in response to BCG","volume":"190","author":"Zhang","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2015.11.073_bib8","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.juro.2012.09.123","article-title":"HMGB1 release by urothelial carcinoma cells is required for the in\u00a0vivo antitumor response to bacillus Calmette-Gu\u00e9rin","volume":"189","author":"Zhang","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2015.11.073_bib9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/(SICI)1097-0320(19961201)25:4<381::AID-CYTO10>3.0.CO;2-R","article-title":"Double fluorescent flow cytometric assessment of bacterial internalization and binding by epithelial cells","volume":"25","author":"de Boer","year":"1996","journal-title":"Cytometry"},{"key":"10.1016\/j.juro.2015.11.073_bib10","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.juro.2013.09.012","article-title":"Loss of BCG viability adversely affects the direct response of urothelial carcinoma cells to BCG exposure","volume":"191","author":"Shah","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2015.11.073_bib11","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1016\/j.juro.2009.08.018","article-title":"MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin","volume":"182","author":"Chen","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2015.11.073_bib12","first-page":"20","article-title":"CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer","volume":"28","author":"Ninalga","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.juro.2015.11.073_bib13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer","volume":"89","author":"Martinez-Pineiro","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2015.11.073_bib14","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial","volume":"174","author":"Martinez-Pineiro","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2015.11.073_bib15","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2015.11.073_bib16","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0022-5347(17)37532-8","article-title":"Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer","volume":"147","author":"Morales","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2015.11.073_bib17","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2015.11.073_bib18","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","article-title":"Bacillus Calmette- Gu\u00e9rin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer","volume":"184","author":"Nepple","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2015.11.073_bib19","first-page":"1611","article-title":"Reduction of bladder tumor growth in mice treated with intravesical bacillus Calmette-Guerin and its correlation with bacillus Calmette-Guerin viability and natural killer cell activity","volume":"43","author":"Shapiro","year":"1983","journal-title":"Cancer Res"},{"key":"10.1016\/j.juro.2015.11.073_bib20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF00184116","article-title":"Specific binding of bacillus Calmette-Guerin to urothelial tumor cells in\u00a0vitro","volume":"12","author":"Schneider","year":"1994","journal-title":"World J Urol"},{"key":"10.1016\/j.juro.2015.11.073_bib21","first-page":"697","article-title":"Bacillus-Calmette-Guerin (bcg) organisms directly alter the growth of bladder-tumor cells","volume":"5","author":"Jackson","year":"1994","journal-title":"Int J Oncol"},{"key":"10.1016\/j.juro.2015.11.073_bib22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1475-2867-9-30","article-title":"Growth inhibition of HeLa cell by internalization of Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Tokyo","volume":"9","author":"Kitamura","year":"2009","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.juro.2015.11.073_bib23","doi-asserted-by":"crossref","first-page":"e56327","DOI":"10.1371\/journal.pone.0056327","article-title":"BCG-mediated bladder cancer immunotherapy: identifying determinants of treatment response using a calibrated mathematical model","volume":"8","author":"Rentsch","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.juro.2015.11.073_bib24","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0022-5347(17)53354-6","article-title":"Immunotherapy of murine transitional cell carcinoma","volume":"128","author":"Lamm","year":"1982","journal-title":"J Urol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534715054233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534715054233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2015.11.073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T03:54:02Z","timestamp":1651204442000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2015.11.073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1016\/j.juro.2015.11.073"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2015.11.073","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}